AbstractObjectivesWe sought to describe the hemodynamic and clinical outcomes for the Freestyle aortic root bioprosthesis (Medtronic, Inc, Minneapolis, Minn) in a large multicenter cohort prospectively followed for 8 years.MethodsA total of 700 patients (651 [93%] >60 years of age) at 8 centers in North America were followed prospectively after aortic valve replacement with the Freestyle stentless bioprosthesis; the implant technique was subcoronary in 500, total root in 162, and root inclusion in 38. Follow-up was 3395 patient-years (4.9 ± 2.3 years per patient). Clinical and echocardiographic follow-up was prospectively obtained at yearly intervals.ResultsFor the subcoronary, total root, and root inclusion groups, actuarial freedom from v...
Objectives The aims of this study were to compare long-term results after homograft versus Freestyle...
This study evaluated the long-term clinical performance of the Mosaic bioprosthesis (Medtronic Inc, ...
This study evaluated the long-term clinical performance of the Mosaic bioprosthesis (Medtronic Inc, ...
AbstractObjectivesWe sought to describe the hemodynamic and clinical outcomes for the Freestyle aort...
ObjectiveStentless xenograft bioprostheses may be the future valve of choice for aortic valve replac...
Background and Aim: Early and mid-term clinical outcomes after aortic valve replacement (AVR) with s...
EZELSOY, MEHMET/0000-0002-8423-5071WOS: 000518864700007PubMed: 32118540Background: the study is pres...
Background: The Freestyle stentless bioprosthesis (FSB) has been demonstrated to be a durable prosth...
Background: We compared the midterm outcome after aortic valve replacement with the Freestyle stentl...
Background: The Medtronic Freestyle bioprosthesis (FSB) provides an alternative to other prostheses ...
Objective: Midterm clinical outcome was evaluated after aortic root replacement with Freestyle ® ste...
Stentless bioprostheses show excellent early hemodynamic performance. However, longevity still remai...
Objectives: Our objective was to examine intermediate-term survival and reinterventions in unselecte...
AbstractObjective: Stentless valves convey important hemodynamic benefits but are used selectively d...
ObjectivesAortic stentless pericardial valves were introduced into clinical practice to combine prop...
Objectives The aims of this study were to compare long-term results after homograft versus Freestyle...
This study evaluated the long-term clinical performance of the Mosaic bioprosthesis (Medtronic Inc, ...
This study evaluated the long-term clinical performance of the Mosaic bioprosthesis (Medtronic Inc, ...
AbstractObjectivesWe sought to describe the hemodynamic and clinical outcomes for the Freestyle aort...
ObjectiveStentless xenograft bioprostheses may be the future valve of choice for aortic valve replac...
Background and Aim: Early and mid-term clinical outcomes after aortic valve replacement (AVR) with s...
EZELSOY, MEHMET/0000-0002-8423-5071WOS: 000518864700007PubMed: 32118540Background: the study is pres...
Background: The Freestyle stentless bioprosthesis (FSB) has been demonstrated to be a durable prosth...
Background: We compared the midterm outcome after aortic valve replacement with the Freestyle stentl...
Background: The Medtronic Freestyle bioprosthesis (FSB) provides an alternative to other prostheses ...
Objective: Midterm clinical outcome was evaluated after aortic root replacement with Freestyle ® ste...
Stentless bioprostheses show excellent early hemodynamic performance. However, longevity still remai...
Objectives: Our objective was to examine intermediate-term survival and reinterventions in unselecte...
AbstractObjective: Stentless valves convey important hemodynamic benefits but are used selectively d...
ObjectivesAortic stentless pericardial valves were introduced into clinical practice to combine prop...
Objectives The aims of this study were to compare long-term results after homograft versus Freestyle...
This study evaluated the long-term clinical performance of the Mosaic bioprosthesis (Medtronic Inc, ...
This study evaluated the long-term clinical performance of the Mosaic bioprosthesis (Medtronic Inc, ...